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In individuals below 65 years of age, primary prevention programs have not been successful
in reducing the risk of cardiovascular disease (CVD) and death. However, no large study to
our knowledge has previously evaluated the effects of prevention programs in individuals
aged 65 years or older. The present cohort study evaluated the risk of CVD in a primary pre-
vention program for community-dwelling 70-year-olds.
Method and findings
In 2012–2017, we included 3,613 community-dwelling 70-year-olds living in Umeå, in the
north of Sweden, in a health survey and multidimensional prevention program (the Healthy
Ageing Initiative [HAI]). Classic risk factors for CVD were evaluated, such as blood pressure,
lipid levels, obesity, and physical inactivity. In the current analysis, each HAI participant was
propensity-score-matched to 4 controls (n = 14,452) from the general Swedish population
using national databases. The matching variables included age, sex, diagnoses, medication
use, and socioeconomic factors. The primary outcome was the composite of myocardial
infarction, angina pectoris, and stroke. The 18,065 participants and controls were followed
for a mean of 2.5 (range 0–6) years. The primary outcome occurred in 128 (3.5%) HAI par-
ticipants and 636 (4.4%) controls (hazard ratio [HR] 0.80, 95% CI 0.66–0.97, p = 0.026). In
HAI participants, high baseline levels of blood pressure and lipids were associated with sub-
sequent initiation of antihypertensive and lipid-lowering therapy, respectively, as well as with
decreases in blood pressure and lipids during follow-up. In an intention-to-treat approach,
the risk of the primary outcome was lower when comparing all 70-year-olds in Umeå,
regardless of participation in HAI, to 70-year-olds in the rest of Sweden for the first 6 years
of the HAI project (HR 0.87, 95% CI 0.77–0.97, p = 0.014). In contrast, the risk was similar in
the 6-year period before the project started (HR 1.04, 95% CI 0.93–1.17, p = 0.03 for
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Conclusions
In this study, a primary prevention program was associated with a lower risk of CVD in com-
munity-dwelling 70-year-olds. With the limitation of this being an observational study, the
associations may partly be explained by improved control of classic risk factors for CVD with
the program.
Author summary
Why was this study done?
• In individuals below 65 years of age, primary prevention programs have not been suc-
cessful in reducing the risk of cardiovascular disease (CVD) and death. However, no
previous large study to our knowledge has evaluated the effects of a primary prevention
program in individuals aged 65 years or older.
What did the researchers do and find?
• In total, 3,613 70-year-olds were included in a health survey and multidimensional pre-
vention program. Each individual was propensity-score-matched to 4 controls from the
Swedish population. Finally, individuals were followed-up for CVD.
• During a mean follow-up time of 2.5 years, the prevention program was associated with
20% lower risk of CVD (hazard ratio [HR] 0.80, 95% CI 0.66–0.97, p = 0.026).
• During the years of the prevention program, the risk of CVD was also 13% lower (HR
0.87, 95% CI 0.77–0.97, p = 0.014) for 70-year-olds overall in the municipality where the
prevention program took part, compared to in the rest of Sweden. In contrast, the risk
of CVD was 4% higher in the municipality than the rest of Sweden before the prevention
program started.
What do these findings mean?
• With the limitation of the observational design, the findings suggest that prevention
programs could reduce the risk of CVD in older individuals by targeting classic risk fac-
tors, such as blood pressure.
Introduction
The leading causes of death and morbidity worldwide are noncommunicable diseases (NCDs),
such as chronic respiratory disease, cancer, diabetes, and, in particular, ischemic heart disease
and stroke [1]. The impact of these NCDs will probably increase with a growing number of
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older people in the future [2], imposing great challenges on care systems. However, many
NCDs share modifiable risk factors such as smoking, substance abuse, unhealthy diet, and
physical inactivity. The World Health Organization (WHO) has concluded that stroke, heart
disease, and type 2 diabetes can be prevented by lifestyle change in at least 80% of the individu-
als affected [3]. In addition, appropriate pharmacological interventions decrease the impact of
risk factors such as hypertension and hyperlipidemia.
Thus, there are several incentives to evaluate strategies that may reduce the risk of our most
common NCDs. Although preventive measures likely are necessary cornerstones of these strat-
egies, a meta-analysis of randomized controlled trials showed that primary prevention pro-
grams involving education and counseling did not reduce the risk of cardiovascular disease
(CVD) and death [4]. This lack of effect may relate to the facts that the mean age in the
included studies was only 50 years and that the risk factor burden was rather low. The lack of
effect in previous studies may also be related to short follow-up times, since preventive mea-
sures in midlife may influence the risk of disease many years later. To the best of our knowl-
edge, no large study has previously evaluated the effects of prevention programs in individuals
aged 65 years or older, in whom risk factors for CVD are much more common. The aim of the
present study was to evaluate the effects of a multiple risk factor program—including collec-
tion and evaluation of classic risk factors for CVD such as blood pressure, lipid levels, obesity,
and physical inactivity, and feedback to participants—on the risk of ischemic heart disease and
stroke in 70-year-old men and women.
Methods
Healthy Ageing Initiative program
The Healthy Ageing Initiative (HAI) is an ongoing primary prevention study in Umeå, a
municipality with 127,000 inhabitants in northern Sweden. The study was initiated in May
2012, and is performed at a single clinic. Three trained research nurses conduct all the testing,
with the support of 2 chief physicians (AN and PN). The eligibility criteria are residence in
Umeå Municipality and age exactly 70 years. There are no exclusion criteria, and public popu-
lation registers are used for recruitment. During the years of this study, 54% of 70-year olds in
Umeå have participated.
The prevention program used in the HAI project is described in detail in S1 Appendix. In
short, all participants arrive fasting at a first visit for measurements of blood glucose and lipids.
Other data collected include a comprehensive self-administered health and lifestyle question-
naire; total, gynoid, and visceral fat mass, measured using dual-energy X-ray absorptiometry;
waist and hip circumference, measured using a measuring tape; and blood pressure, which is
measured in a seated position after at least 10 minutes of rest. Participants are given feedback
on their test results (e.g., blood pressure, BMI, and blood glucose) based on cut points from
current guidelines. In total this first visit takes about 3 hours. The participants are then sent
home with an accelerometer for assessment of physical activity during 1 week. Thereafter, the
participants return for a second visit at which all test results form the basis for a motivational
interview about diet, exercise, and tobacco and alcohol use. In addition, participants are
encouraged to contact their general practitioner for appropriate medication adjustments.
Participants and controls
The aim of the present cohort analysis was to evaluate the HAI prevention program with
respect to CVD. The study protocol was registered on ClinicalTrials.gov on 17 October 2017
(NCT03312439), and we received data files for the present project from the National Board of
Health and Welfare on 21 December 2018. We hypothesized that the prevention program
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would reduce the primary outcome of CVD. However, some analyses, such as those on blood
pressure and lipid levels, were added in response to reviewers’ comments. To evaluate the pre-
vention program, in the primary analysis, we included everyone who participated in HAI dur-
ing 2012–2017, in total 3,617 individuals, of whom 3,613 had complete data. We created a
control group from the general population of Sweden using national registry data. Using the
Register of the Total Population [5], we identified controls who resided in Sweden on 31
December 2005 and who were expected to turn 70 years during the analysis period.
In HAI participants, baseline was the date of the HAI health survey. To assign a baseline
date to controls, we randomly sampled the time interval between the HAI participants’ 70th
birthday and the date of their visit. Next, these sampled intervals were added to the controls’
70th birthday. Controls were excluded from the analysis if they were not alive on their assigned
baseline date, if they had emigrated, or if this date was not in 2012–2017.
In a secondary analysis, the risk of the outcome was compared between all 70-year-old
Umeå residents, irrespective of participation in the HAI project, and 70-year-olds residing in
the rest of Sweden who turned 70 years during 2006–2017. This analysis was divided into 2
periods: the 6 years before the start of HAI (2006–2011) and the first 6 years of the study
(2012–2017). In both periods, baseline dates for non-HAI participants were randomly assigned
as described above.
Confounders
Data on diagnosed medical and psychiatric conditions were collected from the National
Patient Register, a register managed by the National Board of Health and Welfare that covers
all inpatient care in Sweden since 1987 and all specialist outpatient care since 2001 [6]. Data
on prescription medication use were obtained from the Prescribed Drug Register, which cov-
ers all medications sold in Sweden since July 2005. Socioeconomic data (income, education,
and civil status) were collected from the registers of Statistics Sweden and the National Board
of Health and Welfare [5]. Detailed variable definitions are provided in S1 Table.
Outcomes
The primary outcome was the occurrence of ischemic or hemorrhagic stroke, myocardial infarc-
tion, or angina pectoris until 31 December 2017. These events were traced through the National
Patient Register using diagnostic codes I20, I21, and I61–I64 (International Classification of Dis-
eases–10th Revision). In addition, for HAI participants, changes in blood pressure and lipid levels
and prescription of antihypertensive drugs and lipid-lowering therapy were investigated after the
baseline examination. Blood pressure measurements and low-density lipoprotein (LDL)–choles-
terol were obtained by using a script to scan all medical records in primary and specialized health-
care, based on the unique personal identity number given to all Swedish residents.
Statistical analysis
In the primary analysis, we matched each HAI participant to 4 controls, matching exactly on
sex and year of birth, and propensity-score-matching on diagnoses, socioeconomic variables,
and prescription medication use (all variables in Table 1). Propensity scores were estimated
using logistic regression. This model included a square term for disposable income, the only
continuous covariate. The propensity-score match was created using a nearest-neighbor algo-
rithm without replacement (Psmatch2 package for Stata). Match quality (closeness) was deter-
mined using standardized mean differences, where differences of<0.1 were considered
negligible [7]. We compared the risk of the primary outcome in HAI participants and matched
controls using Cox regression, a model that was stratified by matched set.
PLOS MEDICINE A prevention program for cardiovascular disease in older individuals
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003135 June 11, 2020 4 / 17
Table 1. Baseline characteristics of Healthy Ageing Initiative (HAI) participants and the control population before and after matching.
Variable HAI participants Controls Standardized mean difference
Before matching After matching Before matching After matching
N 3,617 653,747 14,452
Age, mean (SD), years 70.5 (0.1) 70.5 (0.1) 70.5 (0.1) 0.01 0.01
Female sex, n (%) 1,824 (50.5) 329,373 (50.7) 9,120 (50.5) 0.01 0.00
Disposable income at age 60 years, mean (SD), 1,000 Swedish kronor 245 (175) 235 (580) 249 (226) 0.02 0.02
Missing data, n 0 462
Educationa, n (%)
Primary 613 (16.9) 194,956 (29.8) 2,387 (16.5) 0.34 0.02
Secondary 1,481 (40.9) 278,087 (42.5) 6,104 (42.2) 0.03 0.03
Post-secondary 1,519 (42.0) 176,329 (27.0) 5,961 (41.1) 0.27 0.02
Missing data, n 4 4,375
Civil statusa, n (%)
Married 2,383 (65.9) 395,790 (60.5) 9,529 (65.9) 0.11 0.00
Never married 317 (8.8) 71,967 (11.0) 1,233 (8.5) 0.08 0.01
Widowed 284 (7.9) 55,644 (8.5) 1,106 (7.7) 0.02 0.01
Divorced 633 (17.5) 129,313 (19.8) 2,584 (17.9) 0.06 0.01
Other, n 0 266
Missing data, n 0 767
Diagnoses, n (%)
Stroke 122 (3.4) 27,215 (4.2) 481 (3.3) 0.04 0.00
Myocardial infarction 168 (4.6) 32,515 (5.0) 664 (4.6) 0.02 0.00
Heart failure 63 (1.7) 16,115 (2.5) 240 (1.7) 0.06 0.01
Angina pectoris 282 (7.8) 47,403 (7.3) 1,125 (7.8) 0.02 0.00
Diabetes 326 (9.0) 88,836 (13.6) 1,368 (9.5) 0.16 0.02
Fracture 570 (15.8) 96,327 (14.7) 2,314 (16.0) 0.03 0.01
Rheumatoid arthritis 79 (2.2) 12,629 (1.9) 326 (2.3) 0.02 0.00
Chronic obstructive pulmonary disease 61 (1.7) 18,912 (2.9) 244 (1.7) 0.09 0
Renal failure 27 (0.7) 9,411 (1.4) 125 (0.9) 0.08 0.02
Crohn disease 29 (0.8) 5,200 (0.8) 107 (0.7) 0.00 0.01
Ulcerative colitis 31 (0.9) 5,803 (0.9) 139 (1.0) 0.00 0.01
Parkinson disease 26 (0.7) 4,127 (0.6) 91 (0.6) 0.01 0.01
Dementia 14 (0.4) 6,865 (1.1) 47 (0.3) 0.11 0.01
Depression 735 (20.3) 144,008 (22.0) 2,947 (20.4) 0.04 0.00
Bipolar disorder 18 (0.5) 4,102 (0.6) 66 (0.5) 0.04 0.01
Alcohol intoxication 31 (0.9) 15,335 (2.3) 97 (0.7) 0.16 0.02
Opioid intoxication 1 (0.03) 692 (0.1) 2 (0.01) 0.05 0.01
Cancer 676 (18.7) 125,498 (19.2) 2,722 (18.8) 0.01 0.00
Medicationsb, n (%)
Antihypertensive 2,083 (57.6) 357,358 (54.7) 8,490 (58.7) 0.06 0.02
Lipid-lowering agent 1,558 (43.1) 256,229 (39.2) 6,260 (43.3) 0.08 0.00
Anticoagulant 1,412 (39.0) 257,188 (39.3) 5,641 (39.0) 0.01 0.00
Neuroleptic 82 (2.3) 20,793 (3.2) 300 (2.1) 0.06 0.01
Hypnotic 955 (26.4) 176,796 (27.0) 3,861 (26.7) 0.01 0.01
Sedative 378 (10.5) 133,857 (20.5) 1,535 (10.6) 0.33 0.01
Immunosuppressant 110 (3.0) 20,357 (3.1) 444 (3.1) 0.00 0.00
aEducation and civil status recorded in the calendar year before the baseline date.
bPrescriptions filled since July 2005.
https://doi.org/10.1371/journal.pmed.1003135.t001
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In the secondary analysis of 70-year-olds in Umeå and those in the rest of the Sweden, asso-
ciations were investigated using unconditional Cox regression. To test whether the associa-
tions were different in the periods before and after HAI started, an interaction term was
created between time period of baseline date (2006–2011 or 2012–2107) and whether individu-
als were Umeå residents (yes or no). The proportional hazards assumption was evaluated for
the models by scaled Schoenfeld residuals. Statistical analyses were performed using Stata ver-
sion 15.0 (StataCorp, College Station, TX, US) and SPSS version 25.0 (IBM, Armonk, NY, US).
p-Values < 0.05 were considered to be significant.
Data linkage and ethics approval
HAI data and national registry data could be linked by unique personal identity numbers,
issued to all residents of Sweden upon birth or immigration. The HAI study and the present
analysis were both approved by the Regional Ethical Review Board in Umeå, Sweden (no. 07-
031M with extensions). Written informed consent was given by all participants. This paper fol-
lows the STROBE reporting guideline (S1 STROBE Checklist).
Results
Study cohort
For the primary analysis, data were available for 3,617 HAI participants (of whom 3,613 had
complete data) and 734,359 potential controls born in 1942–1947. Potential controls were
excluded (n = 80,612) if they emigrated before the assigned baseline date, if the baseline date
was out of range, i.e., not in 2012–2017, or if the baseline date was after their date of death.
Thus, there were 3,613 eligible HAI participants and 653,747 eligible controls. Propensity-
score matching resulted in a final cohort of 3,613 HAI participants and 14,452 controls with
similar baseline characteristics (Table 1). Additional baseline characteristics for participants,
collected in the HAI health study are provided in Table 2. Baseline characteristics for all Umeå
residents are presented in Table 3. Individuals who participated in HAI were generally health-
ier, with lower prevalence of CVD and diabetes, than Umeå residents who did not participate.
Outcome of stroke, myocardial infarction, or angina pectoris
The matched cohort (n = 18,065) was followed for a mean of 2.5 years (range 0–6 years) (Fig
1). During follow-up, the primary outcome of stroke, myocardial infarction, or angina pectoris
occurred in 128 (3.5%) HAI participants and 636 (4.4%) controls (hazard ratio [HR] 0.80, 95%
CI 0.66–0.97, p = 0.026). The HR was similar in the male (HR 0.78, 95% CI 0.62–0.99, p =
0.046) and female (HR 0.79, 95% CI 0.57–1.11, p = 0.31) subcohorts.
In a secondary analysis, we compared the risk of the primary outcome in all 70-year-old
Umeå residents to that in 70-year-old individuals in the rest of Sweden (Table 3). At baseline,
the groups were similar in most respects, the exceptions being education and use of antihyper-
tensives, lipid-lowering agents, and sedatives. In the 6-year period before HAI started (years
2006–2011), the primary outcome occurred in 284 (6.5%) Umeå residents, compared to
27,274 (6.1%) individuals from the rest of Sweden (HR 1.06, 95% CI 0.94–1.19, p = 0.33; Fig 2).
This association changed marginally after adjusting for all confounders (HR 1.04, 95% CI
0.93–1.17, p = 0.51). In contrast, during the first 6 years of the HAI prevention program (years
2012–2017), in which 54% of Umeå residents participated, the outcome occurred in 291
(4.4%) Umeå residents and 31,851 (4.9%) residents of the rest of Sweden (HR 0.87, 95% CI
0.77–0.97, p = 0.03 for interaction; Fig 3), after adjustment for all confounders.
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Blood pressure and LDL-cholesterol in HAI participants
In the 3,617 HAI participants, 53.6% had hypertension stage 2 at baseline (blood
pressure� 140/90 mm Hg), irrespective of treatment, and 1,541 (42.6%) of the participants
were not prescribed any antihypertensive drug before participation in the HAI project. In this
group, antihypertensive drug use after participation in HAI was related to blood pressure at
baseline in HAI (Fig 4). Thus, in individuals with blood pressure of<130/80 mm Hg at base-
line, 4.5% were after HAI prescribed at least 1 dose of antihypertensives, compared to 50.5% of
individuals with a systolic blood pressure of at least 160 mm Hg or a diastolic blood pressure
of at least 100 mm Hg at baseline (p< 0.001 for comparison). After HAI, we could track a total
of 7,744 blood pressure measurements performed in 3,126 HAI participants, at general practi-
tioners or in specialist healthcare. For individuals in HAI with a systolic blood pressure of less
than 130 and a diastolic blood pressure of less than 80 mm Hg (n = 517) at baseline, the fol-
low-up measurements showed that mean systolic blood pressure increased by 9.0 mm Hg
(95% CI 7.4–10.6, p< 0.001), and mean diastolic blood pressure increased nonsignificantly by
0.4 mm Hg (95% CI −0.2 to 0.9, p = 0.16) during follow-up (Figs 5 and 6). In contrast, for par-
ticipants with a systolic blood pressure of at least 160 mm Hg or a diastolic blood pressure of at
least 100 mm Hg (n = 434) at baseline, mean systolic blood pressure decreased by 21.8 mm Hg
(95% CI 19.8–23.8, p< 0.001), and mean diastolic blood pressure decreased by 9.6 mm Hg
(95% CI 8.6–10.6, p< 0.001) after baseline (Figs 5 and 6).
In the HAI participants, 2,055 individuals (55.9%) were not treated with lipid-lowering
therapy at baseline. In these individuals, lipid-lowering therapy after baseline was initiated
based on LDL-cholesterol level at baseline (Fig 7). After baseline, 6,631 follow-up
Table 2. Additional baseline characteristics collected from participants in the Healthy Ageing Initiative study.
Variable Total cohort (n = 3,617) Women (n = 1,817) Men (n = 1,800)
Body composition
Height (cm) 170 ± 9 163 ± 6 176 ± 6
Weight (kg) 77.0 ± 15.0 70.3 ± 13.0 83.7 ± 12.9
BMI (kg/m2) 26.6 ± 4.3 26.4 ± 4.7 26.8 ± 3.8
Waist circumference (cm) 94 ± 13 89 ± 12 99 ± 11
Hip circumference (cm) 103 ± 8 103 ± 9 102 ± 7
Total fat mass (grams)� 27,645 ± 9,089 28,887 ± 9,364 26,389 ± 8,624
Gynoid fat mass (grams)� 4,020 ± 1,418 4,604 ± 1,434 3,429 ± 1,128
Android fat mass (grams)� 2,748 ± 1,190 2,586 ± 1,158 2,912 ± 1,199
Blood pressure
Systolic (mm Hg) 139 ± 17 140 ± 17 138 ± 16
Diastolic (mm Hg) 81 ± 9 81 ± 9 82 ± 9
Blood glucose (mmol/l) 5.7 ± 1.2 5.6 ± 1.3 5.8 ± 1.2
Blood lipids (mmol/l)
Total cholesterol 5.4 ± 1.2 5.8 ± 1.1 5.1 ± 1.2
Low-density lipoprotein cholesterol 3.3 ± 1.1 3.5 ± 1.1 3.0 ± 1.0
High-density lipoprotein cholesterol 1.6 ± 0.5 1.7 ± 0.5 1.4 ± 0.4
Triglycerides 1.3 ± 0.7 1.3 ± 0.7 1.4 ± 0.7
Accelerometer-measured physical activity (steps/day) 7,331 ± 3,093 7,298 ± 3,132 7,364 ± 3,052
Current smoker (n, %) 214, 5.9% 119, 6.5% 95, 5.3%
Except where otherwise noted, data are mean ± standard deviation.
�Measured by dual-energy X-ray absorptiometry.
https://doi.org/10.1371/journal.pmed.1003135.t002
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Table 3. Baseline characteristics of 70-year-old Umeå residents and 70-year-old residents from the rest of Sweden.
Variable Baseline date 2006–2011 Baseline date 2012–2017
Umeå residents Sweden residents SMD� Umeå residents Sweden residents SMD�
N 4,495 446,860 6,665 650,699
Age, mean (SD), years 70.5 (0.1) 70.5 (0.1) 0.02 70.5 (0.1) 70.5 (0.1) 0.00
Female sex, n (%) 2,369 (53.9) 230,478 (51.6) 0.05 3,371 (50.6) 329,993 (50.7) 0.00
Disposable income at age 60 years, mean (SD), 1,000 Swedish kronor 185 (230) 179 (348) 0.01 237 (366) 235 (580) 0.00
Missing data, n 0 148 0 452
Educationa, n (%)
Primary 1,326 (30.3) 178,877 (40.0) 0.23 1,400 (21.0) 194,169 (29.8) 0.22
Secondary 1,875 (42.8) 168,665 (38.0) 0.10 2,823 (42.4) 276,745 (42.5) 0.00
Post-secondary 1,179 (26.9) 92,400 (20.7) 0.15 2,429 (36.4) 175,419 (27.0) 0.20
Missing data, n 15 5,918 13 4,366
Civil statusa, n (%)
Married 2,840 (64.6) 277,076 (62.0) 0.06 4,047 (60.7) 394,126 (60.6) 0.00
Never married 323 (7.3) 37,211 (8.3) 0.04 794 (11.9) 71,490 (11.0) 0.03
Widowed 492 (11.2) 49,763 (11.1) 0.00 552 (8.3) 55,376 (8.5) 0.01
Divorced 740 (16.8) 82,370 (18.4) 0.05 1,272 (19.1) 128,674 (19.8) 0.02
Other, n 0 124 0 266
Missing data, n 0 316 0 767
Diagnoses, n (%)
Stroke 204 (4.6) 17,614 (3.9) 0.04 319 (4.8) 27,018 (4.2) 0.04
Myocardial infarction 163 (3.7) 20,375 (4.6) 0.05 352 (5.3) 32,331 (5.0) 0.02
Heart failure 116 (2.6) 10,739 (2.4) 0.02 174 (2.6) 16,004 (2.5) 0.01
Angina pectoris 383 (8.7) 35,919 (8.0) 0.03 540 (8.1) 47,145 (7.2) 0.04
Diabetes 451 (10.3) 52,056 (11.6) 0.05 820 (12.3) 88,142 (13.5) 0.05
Fracture 506 (11.5) 45,364 (10.2) 0.05 1,132 (17.0) 95,765 (14.7) 0.08
Rheumatoid arthritis 95 (2.2) 7,638 (1.7) 0.04 142 (2.1) 12,556 (1.9) 0.02
Chronic obstructive pulmonary disease 131 (3.0) 10,808 (2.4) 0.04 185 (2.8) 18,788 (2.9) 0.01
Renal failure 39 (0.9) 4,007 (0.9) 0.00 91 (1.4) 9,347 (1.4) 0.01
Crohn disease 19 (0.4) 2,327 (0.5) 0.01 48 (0.7) 5,181 (0.8) 0.01
Ulcerative colitis 28 (0.6) 2,645 (0.6) 0.01 48 (0.7) 5,786 (0.9) 0.03
Parkinson disease 36 (0.8) 2,613 (0.6) 0.03 56 (0.8) 4,097 (0.6) 0.03
Dementia 80 (1.8) 4,726 (1.1) 0.06 85 (1.3) 6,794 (1.0) 0.03
Depression 695 (15.8) 66,112 (14.8) 0.03 1,525 (22.9) 143,218 (22.0) 0.03
Bipolar disorder 11 (0.3) 1,968 (0.4) 0.04 48 (0.7) 4,072 (0.6) 0.02
Alcohol intoxication 63 (1.4) 6,873 (1.5) 0.01 129 (1.9) 15,237 (2.3) 0.04
Opioid intoxication 1 (0.02) 203 (0.05) 0.02 3 (0.05) 650 (0.1) 0.03
Cancer 652 (14.8) 66,400 (14.9) 0.00 1,257 (18.9) 124,917 (19.2) 0.01
Medicationsb, n (%)
Antihypertensive 2,455 (55.9) 210,518 (47.1) 0.19 4,072 (61.1) 355,369 (54.6) 0.14
Lipid-lowering agent 1,589 (36.2) 144,738 (32.4) 0.09 2,990 (44.9) 254,797 (39.2) 0.11
Anticoagulant 1,607 (36.6) 153,512 (34.4) 0.05 2,803 (42.1) 255,797 (39.3) 0.06
Neuroleptic 162 (3.7) 12,565 (2.8) 0.05 271 (4.1) 20,604 (3.2) 0.05
Hypnotic 1,004 (22.8) 94,302 (21.1) 0.05 1,861 (27.9) 175,890 (27.0) 0.02
Sedative 360 (8.2) 63,296 (14.2) 0.23 848 (12.7) 133,387 (20.5) 0.23
(Continued)
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measurements of LDL-cholesterol were obtained in 2,347 individuals from the HAI cohort. As
was the case for blood pressure, LDL-cholesterol levels were reduced depending on the LDL-
levels at baseline (Fig 8). For those with LDL-cholesterol levels above 4.11 mmol/l at baseline, a
mean reduction of 1.3 mmol/l was seen more than 2 years after the initial measurement. In
contrast, LDL-cholesterol did not change in those with LDL-cholesterol < 3.36 mmol/l at
baseline.
Table 3. (Continued)
Variable Baseline date 2006–2011 Baseline date 2012–2017
Umeå residents Sweden residents SMD� Umeå residents Sweden residents SMD�
Immunosuppressant 122 (2.8) 9,309 (2.1) 0.05 247 (3.7) 20,220 (3.1) 0.03
Data are presented for those with a baseline date before (years 2006–2011) and after (years 2012–2017) the Healthy Ageing Initiative program started.
�Standardized mean difference.
aEducation and civil status recorded in the calendar year before the baseline date.
bPrescriptions filled since July 2005.
https://doi.org/10.1371/journal.pmed.1003135.t003
Fig 1. Risk of stroke, myocardial infarction, or angina pectoris in participants of the Healthy Ageing Initiative (HAI, n = 3,613) and
matched controls (n = 14,452). The hazard ratio (HR) is presented for the time to first outcome, and below the figure the number at risk at
each time point is presented, together with the number of outcome events within parentheses.
https://doi.org/10.1371/journal.pmed.1003135.g001
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Discussion
In community-dwelling 70-year-olds, a multidimensional prevention program was associated
with a 20% lower risk of CVD during follow-up. Consistent with the main results, the risk of
CVD was lower in 70-year-olds in the prevention program municipality than in the rest of
Sweden after, but not before, the HAI project was initiated. An analysis of intermediate out-
comes in HAI participants showed that detected hypertension and high blood lipids at baseline
were associated with initiation of therapy, and greater reductions in these risk factors during
follow-up.
To our knowledge, no large randomized or observational study has evaluated the effects of
multidimensional prevention programs on CVD in people aged 65 years or older. In people
aged 50 years on average, a meta-analysis of randomized intervention studies found no effect
of such programs on all-cause mortality or coronary heart disease mortality [4]. The associa-
tions found in the present project could be related to the participants’ older age and greater
number of risk factors at baseline. In support of this hypothesis, the mentioned meta-analysis
did find significant effects on all-cause mortality and CVD in participants with diabetes or
hypertension [4]. It has also been demonstrated previously that the importance of risk factors
for CVD increase with increasing age [8].
Fig 2. Risk of stroke, myocardial infarction, or angina pectoris in 70-year-old Umeå residents and in 70-year-olds from the rest of Sweden
with baseline date in 2006–2011. The hazard ratio (HR) is presented for time to first outcome, and below the figure the number at risk at each
time point is presented, together with the number of outcome events within parentheses.
https://doi.org/10.1371/journal.pmed.1003135.g002
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In addition to the risk factor burden in the study population, the success of a primary preven-
tion program may be determined by the risk factor the program is targeting, and if the program
is modifying a single risk factor or the total risk factor burden. Recently, the Look AHEAD
Research Group found that an intervention program targeting weight loss had no effect on
death or CVD in a large randomized study of overweight and obese individuals with type 2 dia-
betes [9]. According to the authors, one reason for the lack of effect could be good medical man-
agement of risk factors for CVD in primary care, i.e., risk factors other than obesity. This is an
important point, since the most important risk factor for CVD and mortality is probably hyper-
tension [10–12]. In the Look AHEAD study population, systolic blood pressure was on average
130 mm Hg at baseline [9], suggesting a rather good adherence to current knowledge and guide-
lines [13], which likely influenced the chance to show an effect of the intervention. In our popu-
lation, about 50% had stage 2 hypertension at baseline [14], irrespective of pharmacological
treatment, suggesting excellent opportunities for improved blood pressure control.
As such, we were interested in also investigating changes in blood pressure and the use of
blood pressure medications after the HAI prevention program. In participants with baseline
blood pressure below 130/80 mm Hg, 4.5% were dispensed a hypertension drug for the first
time during follow-up. In contrast, about 50% of participants were prescribed an antihyperten-
sive for the first time after baseline if they had a systolic blood pressure of at least 160 mm Hg
Fig 3. Risk of stroke, myocardial infarction, or angina pectoris in 70-year-old Umeå residents and in 70-year-olds from the rest of Sweden
with baseline date in 2012–2017. The hazard ratio (HR) is presented for time to first outcome, and below the figure the number at risk at each
time point is presented, together with the number of outcome events within parentheses.
https://doi.org/10.1371/journal.pmed.1003135.g003
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Fig 4. Initiation of blood pressure treatment in treatment-naïve Healthy Ageing Initiative (HAI) participants based on blood pressure
category at baseline (n = 1,541). Hypertension stage 1: systolic blood pressure of 130–139 mm Hg or diastolic blood pressure of 80–89 mm
Hg. Hypertension stage 2: systolic blood pressure of�140 mm Hg or diastolic blood pressure of�90 mm Hg.
https://doi.org/10.1371/journal.pmed.1003135.g004
Fig 5. Changes in systolic blood pressure after the baseline examination in Healthy Ageing Initiative (HAI) participants, based on blood
pressure category at baseline. The figure is based on a total of 7,744 follow-up measurements in 3,126 HAI participants. Means and standard
deviations are presented. Hypertension stage 1: systolic blood pressure of 130–139 mm Hg or diastolic blood pressure of 80–89 mm Hg.
Hypertension stage 2: systolic blood pressure of�140 mm Hg or diastolic blood pressure of�90 mm Hg. BT, blood pressure.
https://doi.org/10.1371/journal.pmed.1003135.g005
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or a diastolic blood pressure of at least 100 mm Hg. These prescription patterns, favoring those
with higher blood pressure, were accompanied by a blood pressure reduction during follow-
up, especially for those with severe hypertension at baseline. Thus, in participants with a blood
Fig 6. Changes in diastolic blood pressure after the baseline examination in Healthy Ageing Initiative (HAI) participants, based on blood
pressure category at baseline. The figure is based on a total of 7,744 follow-up measurements in 3,126 HAI participants. Means and standard
deviations are presented. Hypertension stage 1: systolic blood pressure of 130–139 mm Hg or diastolic blood pressure of 80–89 mm Hg.
Hypertension stage 2: systolic blood pressure of�140 mm Hg or diastolic blood pressure of�90 mm Hg. BT, blood pressure.
https://doi.org/10.1371/journal.pmed.1003135.g006
Fig 7. Initiation of lipid-lowering therapy (statin) in treatment-naïve Healthy Ageing Initiative (HAI)
participants based on low-density lipoprotein (LDL)–cholesterol levels obtained at baseline (n = 2,055).
https://doi.org/10.1371/journal.pmed.1003135.g007
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pressure of at least 160/100 mm Hg, there was a fast reduction of blood pressure after baseline,
and based on all measurements, a mean reduction in systolic blood pressure of 22 mm Hg dur-
ing follow-up. We also evaluated whether the prevention program was associated with
improved control of hypercholesterolemia. Similar to the findings for blood pressure, treat-
ment with lipid-lowering agents was initiated after baseline based on the lipid levels at the ini-
tial investigation within HAI. Furthermore, LDL-cholesterol during follow-up decreased
based on these prescription patterns. In individuals with LDL-cholesterol levels above 4.11
mmol/l at baseline, a mean reduction of 1.3 mmol/l was seen more than 2 years after the initial
measurement. In contrast, for those with optimal lipid levels at baseline, no changes were seen
during follow-up. Based on the results of randomized controlled studies, it is quite clear that
such reductions in blood pressure and blood lipids are associated with a substantial risk reduc-
tion for CVD [15].
Studies have indicated that risk factors for CVD, such as blood pressure and diabetes, are
better at predicting disease in older than in younger age groups [16–18], probably in part
because older people have more risk factors. Since interventions are usually more effective in
groups with many risk factors [19], these are good reasons to include older people in primary
prevention programs. Of our participants, 6% were smokers, the majority were overweight,
about 50% had stage 2 hypertension at baseline irrespective of treatment, and 25% had diabetes
or fasting glucose impairment. Yet, this burden of risk factors is modest from a global perspec-
tive. According to the American Heart Association, more than 60% of Americans aged 65–74
years have hypertension [20]. In Europe, a recent study of 17 countries showed that 11.5% of
Europeans are smokers [21]. Thus, any effects of our prevention program were likely not
related to an unusually high risk factor burden in the study population. The above-mentioned
studies also indicate that it would be of high interest to investigate the effects of preventive
measures on the risk of CVD in older people from other countries with an even higher risk fac-
tor burden.
Fig 8. Changes in low-density lipoprotein (LDL)–cholesterol levels after the baseline examination in Healthy Ageing Initiative (HAI)
participants, based on LDL-cholesterol at baseline. The figure is based on a total of 6,631 measurements in 2,347 HAI participants.
Participants were categorized in 3 groups based on LDL-cholesterol level at baseline: optimal (<3.36 mmol/l, blue line), intermediate (3.36–
4.11 mmol/l, orange line), and high (>4.11 mmol/l, gray line). Means and standard deviations are presented.
https://doi.org/10.1371/journal.pmed.1003135.g008
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Although the risk factor burden in our population may be regarded as modest in an inter-
national perspective, it would have been unethical to randomize participants to the prevention
program. The disadvantage of not randomizing is that the associations found may be explained
by confounding, although participants and controls were matched closely on many potential
confounders at baseline. To investigate further the possibility of confounding, we performed a
sensitivity analysis that showed that the risk of stroke or ischemic heart disease was similar in
Umeå Municipality and the rest of Sweden prior to the start of the prevention program. Thus,
70-year-old Umeå residents overall were probably not healthier than controls due to self-selec-
tion, as the presence of CVD was similar in Umeå and the rest of Sweden before the HAI proj-
ect started. In contrast, the risk of ischemic heart disease and stroke was 13% lower in 70-year-
olds living in Umeå after the start of the prevention program—in which 54% of 70-year-olds
living in Umeå Municipality participated. The consistent results of these analyses suggest that
confounding does not explain our findings. Different components of the prevention program
may have contributed to the lower risk of CVD found in HAI participants: There may have
been improved medication using drugs known to reduce the risk of CVD, and the motiva-
tional interview, including advice with respect to food intake and increased physical activity,
may have contributed to the lower risk of CVD. Interestingly, a recent meta-epidemiological
study suggested that exercise and drug interventions have similar mortality benefits and effects
in the secondary prevention of ischemic heart disease [22]. Future studies are needed to inves-
tigate whether these findings are generalizable to other populations of community-dwelling
older people.
There are several limitations of the present study that should be acknowledged. In particu-
lar, this is an observational study, and the associations found are not proof of causal effects.
However, as explained above, given the risk factor burden, a randomized trial in this popula-
tion could not have been performed due to ethical reasons. We investigated changes in the
intermediate endpoints blood pressure and lipid levels to evaluate whether the lower risk of
CVD in the HAI participants could be explained by changes in these risk factors. As discussed
above, reductions in both blood pressure and lipid levels were seen, especially in those with
higher values at baseline. Although this may support the main association found with respect
to reduced risk of CVD, these changes were also most likely influenced by regression towards
the mean. Therefore, we can only speculate as to whether any effects on CVD are related to
changes in blood pressure and lipid levels from improved medication and/or from behavior
changes from the motivational interview. The strengths of the study include the large sample
of 70-year-olds included in this study and endpoints of high relevance, captured with high pre-
cision in national registers with a low loss to follow-up. Given that the cohort investigated is
population based, the results are likely generalizable to other 70-year-old men and women.
In summary, a multidimensional primary prevention program was associated with a
reduced risk of ischemic heart disease and stroke in community-dwelling 70-year-olds. The
prevention program was also associated with improved treatment of hypertension and hyper-
cholesterolemia, particularly in participants at higher risk. Given that the risk factor burden
was modest compared to in other countries, it would be interesting and important to see evalu-
ations of similar programs elsewhere. Since the world’s population is ageing, primary preven-
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